Survey: Biosimilars are Gaining Momentum Among Payers

October 20th 2021

AmerisourceBergen/Xcenda survey finds payers believe biosimilars provide costs savings, and they are expected to continuing contracting with manufacturers.

Merck Recalls One Lot of Cubicin

October 20th 2021

Glass was found in one vial of Cubicin, which treats patients with Staph infections of the skin and blood.

Express Scripts to Cover the Biosimilar Semglee

October 20th 2021

Express Scripts will put the first interchangeable biosimilar insulin on its National Preferred Formulary and exclude Lantus, the reference product.

FDA Misses PDUFA Date for Bimekizumab

October 19th 2021

COVID-19 travel restrictions have hindered the FDA’s ability to inspect European manufacturing facilities for bimekizumab, which is under review for the treatment of patients with psoriasis.

FDA Approves ZIMHI to Treat Opioid Overdose

October 19th 2021

ZIMHI is the second product approved by the FDA to counteract opioid, and it is a high-dose naloxone expected to be launched in the first quarter of 2022.